Hologic posts strong Q3 revenues

By LabPulse.com staff writers

July 29, 2021 -- Hologic posted strong revenues for its fiscal third quarter. The company attributed the solid financial results in part to recovery from the COVID-19 pandemic.

For the period (end-June 26), Hologic reported revenue of $1.168 billion, up 42% from $822.9 million for the same quarter last year. It posted third-quarter sales for its Diagnostics division of $665.5 million, up 24% from $524.4 million in 2020.

Finally, the company's net income for the quarter was $268.4 million, an increase of 94.6% over net income reported in the third quarter of 2020.

Hologic gets CE Mark for COVID-19 test
Hologic announced it has received the CE Mark for the use of saliva samples with its Aptima SARS-CoV-2 assay in Europe. The assay also has the CE Mark...
Hologic receives CE Mark for CMV detection assay
Hologic has received the CE Mark for its molecular assay to quantify human cytomegalovirus (CMV). The Aptima CMV Quant assay is the company's first test...
Ink dries on Hologic's deal to buy Mobidiag
Hologic announced the completion of its $808 million acquisition of biotechnology company Mobidiag. The Finnish-French company develops near-patient,...
Hologic's growth continues in Q2
Hologic has continued to post significant increases in revenue, with revenues doubling in the company's second quarter. The growth was driven primarily...
Hologic acquires Diagenode for $159 million
Hologic has purchased European molecular diagnostic assay and epigenetic product developer Diagenode for $159 million in a deal that will expand...

Copyright © 2021 LabPulse.com

Last Updated np 7/29/2021 4:49:23 PM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current